Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)
03/02/2023 - 07:00 AM
Launch offers important and affordable alternative for patients
BRIDGEWATER, N.J. --(BUSINESS WIRE)--
Cosette Pharmaceuticals, Inc. ("Cosette") has obtained the US marketing rights to Betaine Anhydrous for Oral Solution 180gm (“Betaine”) in an agreement with ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) and commenced shipping (NDC #0713-0352-81) to customers this week.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005124/en/
Apurva Saraf , President and CEO of Cosette Pharmaceuticals (Photo: Business Wire)
Apurva Saraf , President and CEO of Cosette, stated "This launch is further evidence of Cosette’s ability to partner globally and bring important drugs to the market, and furthers our transformation into a specialty pharmaceutical company. We stay true to our firm belief of Innovating Every Day, to be a trusted partner of choice, and to continue the important work of serving U.S. patients and prescribers.”
Betaine is used by patients with homocystinuria, a rare genetic condition where too much homocysteine builds up in the body. This launch will provide patients with homocystinuria, and the healthcare providers delivering care to those patients, with a safe, efficacious and accessible treatment option.
See the Full Prescribing Information and Instructions for Use for Betaine Anhydrous for Oral Solution, 180 grams. www.dailymed.com
Cystadane® is registered trademark of Recordati Rare Diseases
About Cosette Pharmaceuticals, Inc. :
Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. Cosette has a fast-growing portfolio of branded pharmaceuticals consisting of products in the cardiology, women’s health and migraine markets. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories, which has led to consistent supply to customers and commercialization success. Cosette has corporate and manufacturing facilities in New Jersey and North Carolina , and is supported by more than 350+ dedicated employees across all functional areas. Cosette is backed by Avista Capital Partners , a healthcare focused private equity firm. www.cosettepharma.com
Follow us on LinkedIn.
View source version on businesswire.com : https://www.businesswire.com/news/home/20230302005124/en/
Serge Ilin-Schneider :bd@cosettepharma.com
Kian Kazemi :sales@cosettepharma.com
Source: Cosette Pharmaceuticals, Inc.
ANIP Rankings
#367 Ranked by Stock Gains
ANIP Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Baudette
About ANIP
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
